DICE Therapeutics
Paul, Senior Vice President of Medicinal Chemistry, joined DICE Therapeutics in October 2018 as Vice President of Medicinal Chemistry in the Early Development group. He has over 25 years of medicinal chemistry experience in roles of increasing leadership and has successfully overseen the chemistry and early CMC activities for multiple research programs. Most recently, Paul was at ViewPoint Therapeutics where he was the Vice President of Chemistry overseeing the discovery and early development of small molecule correctors of misfolded proteins. Prior to ViewPoint Therapeutics, Paul was at Theravance Biopharma as a Senior Director of Chemistry where he was involved in the identification of over 7 differentiated clinical candidates across multiple indications, target classes, and routes of administration including Vibativ® (telavancin), Velusetrag (TD-5108), Cefilavancin (TD-1792), and TD-8236 a novel, inhaled pan-JAK inhibitor.
Prior to Theravance BioPharma, Paul was a chemist at Arris Pharmaceuticals and Syntex Research. Paul holds a B.S. in Chemistry from the University of California, Santa Barbara.
This person is not in any offices
DICE Therapeutics
At DICE Therapeutics, we design and develop innovative therapies in immunology for patients with debilitating disease. Seeking to create a future where convenient oral medicines with biologic-like efficacy are available to patients with serious medical conditions, we are developing oral alternatives to medicines currently limited to injectable forms. We believe that such pills will be widely appreciated by patients and doctors alike, as they provide a lower bar to entry than biologics, and as oral medicines can easily be co-formulated with other efficacious drugs. The combination of our core technology with additional, unique biophysical insights has enabled DICE to target protein-protein interactions with small molecules. In doing so, DICE has cracked open a previously intractable set of clinically validated therapeutic targets, including Interleukin-17 (IL-17). Our lead program – an orally bioavailable IL-17 antagonist for the treatment of psoriasis – is currently progressing through IND-enabling studies. In parallel, we continue to advance both partnered and internal pipeline drug discovery programs, providing a robust pre-clinical pipeline.